Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AMBSNASDAQ:HEPANYSE:NAVBOTCMKTS:QBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMBSAmarantus Bioscience$0.00$0.00▼$0.00N/A1.890 shsN/AHEPAHepion Pharmaceuticals$0.08+14.0%$0.15$0.04▼$56.00$874K1.581.31 million shs55,421 shsNAVBNavidea Biopharmaceuticals$0.00+900.0%$0.00$0.00▼$0.13$100K1.78,538 shs5,492 shsQBIOQ Biomed$0.00$0.00$0.00▼$0.03N/A2.224,600 shs14,151 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMBSAmarantus Bioscience0.00%0.00%0.00%+200.00%+200.00%HEPAHepion Pharmaceuticals0.00%-12.25%+8.00%-83.67%-99.86%NAVBNavidea Biopharmaceuticals0.00%-50.00%-85.71%-75.00%-80.00%QBIOQ Biomed0.00%0.00%0.00%-50.00%+∞Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMBSAmarantus BioscienceN/AN/AN/AN/AN/AN/AN/AN/AHEPAHepion Pharmaceuticals0.2997 of 5 stars0.03.00.00.01.10.00.6NAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AQBIOQ BiomedN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMBSAmarantus Bioscience 0.00N/AN/AN/AHEPAHepion Pharmaceuticals 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/AQBIOQ Biomed 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMBSAmarantus BioscienceN/AN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/ANAVBNavidea Biopharmaceuticals$8.13K12.32N/AN/AN/A∞QBIOQ Biomed$280KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMBSAmarantus BioscienceN/AN/A0.00N/AN/AN/AN/AN/AN/AHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%8/11/2025 (Estimated)NAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/AQBIOQ Biomed-$2.05MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMBSAmarantus BioscienceN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AQBIOQ BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMBSAmarantus BioscienceN/AN/AN/AHEPAHepion PharmaceuticalsN/A1.301.30NAVBNavidea BiopharmaceuticalsN/AN/AN/AQBIOQ BiomedN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMBSAmarantus BioscienceN/AHEPAHepion Pharmaceuticals17.24%NAVBNavidea Biopharmaceuticals0.01%QBIOQ BiomedN/AInsider OwnershipCompanyInsider OwnershipAMBSAmarantus Bioscience10.33%HEPAHepion Pharmaceuticals0.06%NAVBNavidea Biopharmaceuticals43.68%QBIOQ Biomed28.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMBSAmarantus Bioscience12N/AN/ANot OptionableHEPAHepion Pharmaceuticals2010.93 million6.63 millionNo DataNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableQBIOQ Biomed3N/AN/ANot OptionableQBIO, AMBS, HEPA, and NAVB HeadlinesRecent News About These CompaniesQ BioMed IncApril 8, 2025 | uk.investing.comOrchestra Biomed Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comOrchestra BioMed Reports Q3 2024 Results, Advances Key Clinical ProgramsNovember 14, 2024 | msn.comIBM's newest 156-qubit quantum chip can run 50 times faster than its predecessor — equipping it for scientific researchNovember 14, 2024 | msn.comFormer Bigfoot Biomedical CEO takes corner office at AI medtech company Q-BioOctober 11, 2024 | massdevice.comA Powerful New Tool for Biomedical ResearchSeptember 12, 2024 | msn.comOpinion: Artificial intelligence already improving biomedical research, health careSeptember 5, 2024 | sandiegouniontribune.comSClearmind Biomedical wins FDA clearance for Neuroblade minimally invasive neuroendoscopy techAugust 27, 2024 | massdevice.comMayo Clinic taps startup SandboxAQ to study new tech — quantum sensing and AI — for cardiac diagnosticsAugust 8, 2024 | fiercehealthcare.comF18th Annual Q-Bio Conference: Global scholars explore new Frontiers in quantitative biologyAugust 7, 2024 | eurekalert.orgEE&Q Master Cordless Gutta Percha Obturator from Meta BioMedMarch 24, 2024 | news-medical.netNClearside Biomedical Q4 2023 Earnings PreviewMarch 11, 2024 | msn.comQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and DatesFebruary 24, 2024 | benzinga.comBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue EstimatesFebruary 13, 2024 | msn.comBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthJanuary 28, 2024 | msn.comQ BioMed Inc QBIONovember 16, 2023 | morningstar.comMBiomedical Sciences PhD ProgramNovember 13, 2023 | uwyo.eduUQ&A: How generative AI could help accelerate biomedical researchNovember 6, 2023 | phys.orgPQBIO Q BioMed Inc.August 18, 2023 | seekingalpha.comQ BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in EuropeApril 17, 2023 | pharmabiz.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQBIO, AMBS, HEPA, and NAVB Company DescriptionsAmarantus Bioscience OTCMKTS:AMBSAmarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.Hepion Pharmaceuticals NASDAQ:HEPA$0.08 +0.01 (+13.96%) As of 03:26 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Navidea Biopharmaceuticals NYSE:NAVB$0.0010 +0.00 (+900.00%) As of 03:15 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Q Biomed OTCMKTS:QBIO$0.0001 0.00 (0.00%) As of 09:57 AM EasternQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
